Related references
Note: Only part of the references are listed.A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
V. Guarneri et al.
ANNALS OF ONCOLOGY (2009)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Invasive ductal carcinoma of the breast with the triple-negative phenotype: prognostic implications of EGFR immunoreactivity
Giuseppe Viale et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Should we be surprised at the paucity of response to EGFR inhibitors?
Barry A. Gusterson et al.
LANCET ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
Luiz Gonzaga Almeida et al.
NUCLEIC ACIDS RESEARCH (2009)
CT-X antigen expression in human breast cancer
Anita Grigoriadis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer:: Predictive value of centrally reviewed expression of estrogen and progesterone receptors -: International Breast Cancer Study Group
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
Giuseppe Viale et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes
Akosua B. Domfeh et al.
MODERN PATHOLOGY (2008)
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming
Djordje Atanackovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Genome-wide analysis of cancer/testis gene expression
Oliver Hofmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer
Kunle Odunsi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
Danila Valmori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
NY-ESO-1 protein expression in primary breast carcinoma and metastases - Correlation with CD8+T-cell and CD79a+plasmacytic/B-cell infiltration
Jean-Philippe Theurillat et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
BRCA1, a potential predictive biomarker in the treatment of breast cancer
Colin R. James et al.
ONCOLOGIST (2007)
Vaccine immunotherapy in breast cancer treatment: promising, but still early
Giuseppe Curigliano et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Deconstructing the molecular portrait of basal-like breast cancer
Fruma Yehiely et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Recombinant vaccinia/fowipox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
Elke Jaeger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer
A Mischo et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells
N van Baren et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer
AO Gure et al.
CLINICAL CANCER RESEARCH (2005)
Proliferation marker Ki-67 in early breast cancer
A Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer/testis antigens, gametogenesis and cancer
AJG Simpson et al.
NATURE REVIEWS CANCER (2005)
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
Y Sugita et al.
CANCER RESEARCH (2004)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
MJ Scanlan et al.
IMMUNOLOGICAL REVIEWS (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours
A. A. Jungbluth et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
